Promis Neurosciences (PMN) Competitors $0.55 +0.02 (+4.59%) Closing price 08/21/2025 04:00 PM EasternExtended Trading$0.56 +0.01 (+2.37%) As of 09:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. ELUT, WHWK, IGMS, AVTE, CELU, JMAC, QNTM, PMVP, ASRT, and FBRXShould you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include Elutia (ELUT), Whitehawk Therapeutics (WHWK), IGM Biosciences (IGMS), Aerovate Therapeutics (AVTE), Celularity (CELU), Maxpro Capital Acquisition (JMAC), Quantum Biopharma (QNTM), PMV Pharmaceuticals (PMVP), Assertio (ASRT), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry. Promis Neurosciences vs. Its Competitors Elutia Whitehawk Therapeutics IGM Biosciences Aerovate Therapeutics Celularity Maxpro Capital Acquisition Quantum Biopharma PMV Pharmaceuticals Assertio Forte Biosciences Promis Neurosciences (NASDAQ:PMN) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Which has more risk & volatility, PMN or ELUT? Promis Neurosciences has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Do insiders & institutionals believe in PMN or ELUT? 50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 6.1% of Promis Neurosciences shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to PMN or ELUT? In the previous week, Elutia had 4 more articles in the media than Promis Neurosciences. MarketBeat recorded 4 mentions for Elutia and 0 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.00 beat Elutia's score of 0.36 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Promis Neurosciences Positive Elutia Neutral Is PMN or ELUT more profitable? Promis Neurosciences has a net margin of 0.00% compared to Elutia's net margin of -90.01%. Elutia's return on equity of 0.00% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -266.69% -131.59% Elutia -90.01%N/A -54.08% Do analysts prefer PMN or ELUT? Promis Neurosciences presently has a consensus target price of $4.33, suggesting a potential upside of 689.31%. Elutia has a consensus target price of $8.00, suggesting a potential upside of 263.64%. Given Promis Neurosciences' higher probable upside, equities research analysts clearly believe Promis Neurosciences is more favorable than Elutia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, PMN or ELUT? Promis Neurosciences has higher earnings, but lower revenue than Elutia. Promis Neurosciences is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.21-2.61Elutia$23.68M3.82-$53.95M-$1.06-2.08 SummaryElutia beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks. Get Promis Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.16M$3.09B$5.79B$9.58BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-2.6120.4330.4725.19Price / SalesN/A377.07454.63115.75Price / CashN/A43.0937.1558.42Price / Book-54.907.919.036.24Net Income$2.78M-$54.72M$3.26B$265.30M7 Day Performance-11.02%-0.09%0.40%-0.84%1 Month Performance-33.04%4.49%3.23%-1.53%1 Year Performance-56.08%10.15%29.53%17.73% Promis Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNPromis Neurosciences3.0343 of 5 stars$0.55+4.6%$4.33+689.3%-55.4%$17.16MN/A-2.615Positive NewsELUTElutia3.6492 of 5 stars$1.99+1.0%$8.00+302.0%-43.7%$81.00M$23.71M-1.03180Analyst RevisionWHWKWhitehawk TherapeuticsN/A$1.71+1.2%N/AN/A$79.65M$25.98M-28.5040IGMSIGM Biosciences4.427 of 5 stars$1.30+0.8%$5.50+323.1%N/A$77.78M$2.68M-1.44190AVTEAerovate TherapeuticsN/A$7.40-1.2%N/A-88.8%$77.68MN/A-2.4720High Trading VolumeCELUCelularity0.7356 of 5 stars$3.06-5.3%N/A+13.7%$77.36M$54.22M-1.15220JMACMaxpro Capital AcquisitionN/A$5.69+0.3%N/A+4,234.1%$76.41MN/A0.002,021QNTMQuantum BiopharmaN/A$24.33-7.3%N/AN/A$76.35MN/A-1.74N/AHigh Trading VolumePMVPPMV Pharmaceuticals2.3259 of 5 stars$1.42+1.4%$5.50+287.3%-7.5%$74.19MN/A-0.9050ASRTAssertio2.2279 of 5 stars$0.83+14.5%$2.38+186.1%-40.3%$69.44M$124.96M-1.8420Gap DownHigh Trading VolumeFBRXForte Biosciences2.978 of 5 stars$10.76+2.4%$61.00+466.9%+83,812.4%$69.19MN/A-0.665News CoverageOptions Volume Related Companies and Tools Related Companies Elutia Alternatives Whitehawk Therapeutics Alternatives IGM Biosciences Alternatives Aerovate Therapeutics Alternatives Celularity Alternatives Maxpro Capital Acquisition Alternatives Quantum Biopharma Alternatives PMV Pharmaceuticals Alternatives Assertio Alternatives Forte Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access